MBX Biosciences (MBX) financial statements
Net income was -$87M.
Free cash flow was -$82M.
The diluted share count rose 3483% over the period (dilution).
Income statement
Fiscal years, from MBX Biosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | $29M | $57M | $79M |
| Selling, general and admin | $7M | $11M | $19M |
| Operating income | -$35M | -$68M | -$98M |
| Pre-tax income | — | -$62M | -$87M |
| Income tax | $0 | $0 | $0 |
| Net income | -$33M | -$62M | -$87M |
| EPS (diluted) | -$31.96 | -$5.82 | -$2.38 |
| Diluted shares | 1M | 11M | 37M |
Balance sheet
Fiscal years, from MBX Biosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $81M | $262M | $374M |
| Total current assets | $83M | $267M | $382M |
| Property, plant and equipment | $439,000 | $1M | $3M |
| Total assets | $84M | $269M | $385M |
| Total current liabilities | $4M | $11M | $15M |
| Total liabilities | $4M | $11M | $16M |
| Shareholders' equity | -$72M | $257M | $369M |
| Net debt | -$31M | -$49M | -$75M |
Cash flow
Fiscal years, from MBX Biosciences's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$32M | -$55M | -$80M |
| Capital spending | $129,000 | $874,000 | $2M |
| Free cash flow | -$32M | -$56M | -$82M |
| Stock-based compensation | $2M | $5M | $9M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MBX.
Open MBX in InvestinglyQuestions
How much free cash flow does MBX Biosciences generate?
-$82M in fiscal 2025 (operating cash flow minus capital spending).
From MBX Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.